Decisions, Decisions: Selecting Among the Increasing Array of Treatments and Combinations for Patients With Advanced BRAF-Positive Melanoma
Advances in BRAF-targeted agents and their integration into treatment algorithms for patients diagnosed with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. However, for patients diagnosed with advanced disease, challenges exist for identifying those who will benefit from first-line targeted therapy versus immune-based therapies. Recent data on triple therapy combining dual BRAF and MEK inhibition (BRAFi/MEKi) with anti-programmed cell death (anti-PD1) checkpoint blockade in the first-line setting for advanced disease has added yet another option for consideration. The optimal sequencing of regimens for treating advanced BRAF-mutated melanoma remains a very active area of investigation. As data become available on new combination and sequencing approaches, as well as treatment-associated toxicity, ongoing education is needed to guide clinicians in the selection of appropriate therapy based on patient and disease characteristics. In this educational activity, experts present emerging data on targeted agents, checkpoint inhibitors, and combinations for patients with BRAF-mutated melanoma. They will review patient, disease, and/or treatment characteristics that may inform clinical decision-making on initial therapy for advanced disease. And finally, faculty will discuss emerging combination approaches, including sequencing and toxicity considerations, for patients with advanced BRAF-positive melanoma. This expert panel discussion features an interactive learning platform and case discussions to provide insight on how new developments in the treatment of BRAF-mutated melanoma may impact clinical care.
Cost: FreeView Offer chevron_right
- 1.0 AMA PRA Category 1 Credit(s)™
- 43% of activities take less than 30 minutes to complete
- The My Healio CME Dashboard keeps track of earned credits and saved activities
- Personalized recommendations make finding your next activity easy
- Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
- BRAF-Positive Melanoma
- BRAF-Mutated Melanoma
Upon successful completion of this educational activity, participants should be better able to:
-Assess the latest evidence regarding the use of targeted agents, checkpoint inhibitors, and combinations for patients with BRAF-mutated melanoma.
-Describe patient, disease, and/or treatment characteristics that may inform first-line clinical decision making for patients with BRAF-mutated melanoma and apply to practice accordingly.
-Review emerging combination approaches, including sequencing and toxicity considerations, for patients with advanced BRAF-positive melanoma and how these approaches may impact clinical care.
The intended audience for this activity is hematologist-oncologists, oncologists and other health care professionals involved in the management of patients with advanced BRAF-positive melanoma.
Additional credit info
This continuing medical education activity is provided by: National Jewish Health
Educational Partner: Vindico Medical Education
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 15, 2020, to December 14, 2021.